This research investigates polyploid giant cancer cells, a highly treatment-resistant population responsible for cancer relapse. By studying their structural biology and dependence on lipid metabolism, the work identifies metabolic vulnerabilities that can be targeted alongside chemotherapy, offering a promising strategy to eliminate resistant cancer cells and improve long-term treatment outcomes.

This research investigates a new targeted treatment strategy for kidney cancer by inhibiting the cancer-promoting protein PIM1 while enhancing TRAIL-mediated apoptosis. Together with the FDA-approved drug ONC201, this combination restores cancer cells' ability to self-destruct, offering a promising therapeutic approach now being evaluated in preclinical studies.

This research engineers DNA-modified exosomes to deliver drugs precisely to cancer cells while avoiding healthy tissue. By disguising natural cell-targeting signals and adding programmable DNA targeting molecules, the platform could reduce treatment side effects and provide a modular delivery system adaptable to many cancers and other diseases.

This research develops orally administered nanoparticle therapies for metronomic chemotherapy in ovarian cancer. By delivering smaller drug doses directly to tumours over extended periods, it aims to reduce side effects, overcome drug resistance, improve patient quality of life, and make long-term cancer treatment easier and more effective.

This research develops gold nanoparticles coated with peptides to block DNA repair in colorectal cancer cells, helping overcome drug resistance. Laboratory studies show the treatment dramatically reduces cancer cell survival after radiation while minimising toxicity. The approach could provide a safer, more effective therapy for colorectal cancer and other drug-resistant cancers.

This research develops nanobubble-enhanced ultrasound imaging as an accessible alternative to MRI for cancer diagnosis. Tiny gas-filled nanoparticles amplify ultrasound signals and improve image quality, particularly in prostate cancer. The technology could reduce diagnostic delays, lower costs, and provide high-quality medical imaging to more patients worldwide.

This research develops “nanozymes,” nanoparticle-based catalysts that activate cancer drugs directly at tumor sites. Instead of carrying large amounts of chemotherapy drugs, nanozymes locally trigger inactive drugs into their active form only within cancer tissue. Early mouse studies show effective tumor destruction with significantly reduced side effects compared to conventional chemotherapy.

This research uses artificial intelligence to predict the progression of Alzheimer’s disease and cancer using medical imaging data. By analyzing brain scans, tumor scans, and treatment responses, AI models can forecast disease development and treatment outcomes, enabling earlier intervention, more personalized care, and improved quality of life for aging populations.

This research investigates taste alterations experienced by cancer patients during chemotherapy and radiotherapy. Using electrogustometry and flavour profile analysis, the study measures and categorizes changes in taste perception to guide the development of tailored food products that improve nutrition, comfort, and quality of life for people undergoing cancer treatment.

This research develops nanoscale “smart package” delivery systems for PROTAC cancer drugs. Antibody nanogel conjugates selectively target cancer cells, enter them, and release therapeutic molecules while minimizing exposure to healthy tissue. The approach improves delivery efficiency and aims to reduce the severe side effects that often limit cancer treatment.